Daily Newsletter

13 March 2024

Daily Newsletter

13 March 2024

Allumiqs and Prolytix collaborate for drug discovery

Once the early R&D phase is completed using Allumiqs expertise, customers can move to Prolytix for targeted method development.

Vishnu Priyan March 13 2024

Allumiqs has entered into a long-term strategic collaboration with Prolytix to expedite the discovery and development of new drugs.

The alliance aims to deliver partnered and integrated offerings that enhance the efficiency of drug development pipelines, providing customers with advanced bioanalytical support.

Such solutions will facilitate in progressing drug candidates from the initial research and development (R&D) phases through to commercialisation.

Allumiqs serves as a contract research organisation (CRO) solutions partner for biotech and biopharma companies.

With its liquid chromatography with tandem mass spectrometry (LC-MS) and multiomics expertise, data analytics and insights, the CRO aids in saving the cost and time required for drug development.

The company offers both on-demand and tailored solutions to support the progression of drug candidates.

The latest partnership builds on a history of successful joint customer engagements.

Allumiqs will provide its proficiency in multiomics and LC-MS solutions, while Prolytix will contribute its broad experience in large-molecule drug product life cycle management.

Together, they provide cohesive solutions that could streamline the drug development process.

Allumiqs plays a crucial role in the early R&D phases by offering biological insights and therapeutic characterisation, comprising mechanism of action, biomarker detection and drug product characteristics.

Once this is complete, customers move to Prolytix for targeted method development which encompasses stability, potency and good manufacturing practice release testing.

The partnership ensures the smooth transition of critical R&D work, minimising the complexities and risks associated with engaging separate vendors.

The combined expertise of Allumiqs and Prolytix will offer customers a unified team of specialists, streamlining the drug development process and reducing the time to market for new therapies.

Allumiqs CEO Kent MacLean stated: “We found many synergies in working with the team at Prolytix in collaborative customer projects, most importantly our shared commitment to customer success.

“Now, in partnership with Prolytix, we can take all of our customers further in the drug development process with connected solutions from early R&D to lot release. Our goal is to make it simple for our customers to engage with the innovation partners they need at every stage of the drug discovery process, and our partnership with Prolytix does that.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.